• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reply to Béranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children".对贝朗热等人《连续性肾脏替代治疗在美罗培南群体药代动力学模型中在危重症儿童中的整合》一文的回复
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02592-20.
2
Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children.连续性肾脏替代疗法纳入美罗培南群体药代动力学模型在危重症儿童中的应用
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02542-20.
3
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.肾功能在标准剂量美罗培南治疗危重症患者后目标未达标风险评估中的作用：一项前瞻性观察研究。
Crit Care. 2017 Oct 21;21(1):263. doi: 10.1186/s13054-017-1829-4.
4
Population pharmacokinetics of meropenem in critically ill children with different renal functions.重症患儿不同肾功能人群中美罗培南的群体药代动力学。
Eur J Clin Pharmacol. 2020 Jan;76(1):61-71. doi: 10.1007/s00228-019-02761-7. Epub 2019 Oct 26.
5
Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.接受持续肾脏替代治疗的儿童美罗培南的药代动力学：临床试验模拟的验证
J Clin Pharmacol. 2016 Mar;56(3):291-7. doi: 10.1002/jcph.601. Epub 2015 Sep 21.
6
Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.连续肾脏替代治疗危重症患者标准剂量美罗培南的群体药代动力学：一项前瞻性观察性研究。
Pharmacol Rep. 2020 Jun;72(3):719-729. doi: 10.1007/s43440-020-00104-3. Epub 2020 Apr 16.
7
Pharmacokinetics of meropenem during advanced organ support (ADVOS) and continuous renal replacement therapy.美罗培南在高级器官支持（ADVOS）和连续肾脏替代治疗期间的药代动力学。
Int J Artif Organs. 2021 Oct;44(10):783-786. doi: 10.1177/03913988211021101. Epub 2021 Jun 18.
8
The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.肾脏替代治疗方案中的变异性对危重症患者哌拉西林、美罗培南和万古霉素药物清除率的影响：文献分析和剂量方案*。
Crit Care Med. 2014 Jul;42(7):1640-50. doi: 10.1097/CCM.0000000000000317.
9
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.通过动态中空纤维感染模型评估危重症患者药代动力学改变对美罗培南抗菌效果的重大影响。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02642-16. Print 2017 May.
10
Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.重新评估美罗培南在重症婴幼儿中的最佳剂量：一项发育性药代动力学-药效学分析。
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00760-20.

本文引用的文献

1
Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children.连续性肾脏替代疗法纳入美罗培南群体药代动力学模型在危重症儿童中的应用
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02542-20.
2
Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.美罗培南在重症儿科患者中的群体药代动力学和药效学。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01909-20.
3
Population pharmacokinetics of meropenem in critically ill children with different renal functions.重症患儿不同肾功能人群中美罗培南的群体药代动力学。
Eur J Clin Pharmacol. 2020 Jan;76(1):61-71. doi: 10.1007/s00228-019-02761-7. Epub 2019 Oct 26.
4
Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.儿科连续性肾脏替代治疗中应用体外模型的抗菌药物处置。
Crit Care Med. 2019 Sep;47(9):e767-e773. doi: 10.1097/CCM.0000000000003895.
5
Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion.美罗培南复溶后通过延长输注给药的稳定性。
Hosp Pharm. 2019 Jun;54(3):190-196. doi: 10.1177/0018578718779009. Epub 2018 May 30.
6
Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.描述肾脏替代治疗模式和参数对美罗培南和沃班巴坦药代动力学的影响。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01306-18. Print 2018 Oct.
7
Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.小儿静脉-静脉体外膜肺氧合期间药物的药代动力学
J Thorac Dis. 2018 Mar;10(Suppl 5):S642-S652. doi: 10.21037/jtd.2017.11.02.
8
Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation.接受体外膜肺氧合治疗的危重症成年患者药物药代动力学改变的评估
Pharmacotherapy. 2017 Feb;37(2):221-235. doi: 10.1002/phar.1882. Epub 2017 Feb 3.
9
Investigation of Key Circuit Constituents Affecting Drug Sequestration During Extracorporeal Membrane Oxygenation Treatment.体外膜肺氧合治疗期间影响药物螯合的关键电路成分研究。
ASAIO J. 2017 May/Jun;63(3):293-298. doi: 10.1097/MAT.0000000000000489.
10
Determinants of drug absorption in different ECMO circuits.不同 ECMO 回路中药物吸收的决定因素。
Intensive Care Med. 2010 Dec;36(12):2109-16. doi: 10.1007/s00134-010-2041-z. Epub 2010 Sep 23.

Reply to Béranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children".

作者信息

Saito Jumpei, Shoji Kensuke, Oho Yusuke, Kato Hiroki, Matsumoto Shotaro, Aoki Satoshi, Nakamura Hidefumi, Ogawa Takanori, Hasegawa Mayumi, Yamatani Akimasa, Miyairi Isao

机构信息

Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan

Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.

出版信息

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02592-20.

DOI:10.1128/AAC.02592-20
PMID:33495216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8097448/
Abstract
摘要